Standard BioTools Inc.

What they do

Standard BioTools sells instrumentation, consumables and services for biomedical research across proteomics and genomics. Its continuing platforms are CyTOF (mass cytometry single-cell analysis detecting 50+ markers), Hyperion (imaging mass cytometry for spatial tissue analysis of up to 40+ protein markers), and Biomark X9 (microfluidics-based high-throughput qPCR). It sold the aptamer-based SomaScan business, including KREX, Single SOMAmer and Sengenics, to Illumina, a transaction that closed January 30, 2026.

Revenue drivers

• Consumables — Largest continuing revenue line at $9.4 million in Q2 2026, down 10% year-over-year on soft US academia spending.
• Services (predominantly Field Services) — Second-largest line at $5.6 million in Q2 2026, down 8% year-over-year.
• Instruments — Smallest line at $5.1 million in Q2 2026, down 2% year-over-year, held back by capital-constrained end markets.

Recent performance

Second quarter 2026 revenue was $20.1 million, down 7.6% year-over-year, with all three lines declining. Gross margin improved to 52.4% from 48.8%, and non-GAAP gross margin to 56.3% from 54.1%, on productivity improvements and lower warranty expense. Operating loss was $25.4 million versus $25.7 million a year earlier, while adjusted EBITDA improved 84% to negative $2.5 million from negative $16.1 million. Non-GAAP operating expenses fell 50% to $13.8 million. Net loss from continuing operations was $21.5 million, compared with $17.7 million in the prior-year quarter.

Strategy

Management is pursuing a merger with Treeline Biosciences, anticipated to close before year-end 2026, following a filed Form S-4 and an agreement to divest the Mass Cytometry business. Illumina exercised an early buyout of contingent payments from the SomaLogic acquisition for $30 million. The company is emphasizing cost discipline, which drove the year-over-year adjusted EBITDA improvement. It also faces a delisting notice and a June 2026 change-in-control event, per recent 8-K filings.

Risks

• Merger execution — The Treeline merger still requires a stockholder vote and is subject to closing conditions, with management targeting completion before year-end 2026.
• Listing status — The company disclosed a delisting notice or listing-rule failure on July 24, 2026, which could affect the Nasdaq listing of its common stock.
• Declining core revenue — Continuing-operations revenue fell 7.6% year-over-year in Q2 2026, with consumables down 10%, instruments down 2% and services down 8%.
• End-market funding pressure — Results are affected by US academia spend uncertainty and capital-constrained instrument buyers, which the company cites in its outlook.

Outlook

Management says it remains on track to close the Treeline Biosciences merger in 2026 and believes the deal is the best path to maximize shareholder value. It describes the combined company as a catalyst-rich, well-capitalized pipeline of potential new therapeutics. No specific revenue or earnings guidance is given in the excerpts provided.